MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
1.045
-0.105
-9.13%
Opening 13:32 09/29 EDT
OPEN
1.150
PREV CLOSE
1.150
HIGH
1.160
LOW
1.035
VOLUME
229.10K
TURNOVER
127.97K
52 WEEK HIGH
5.95
52 WEEK LOW
1.035
MARKET CAP
170.72M
P/E (TTM)
-0.9344
1D
5D
1M
3M
1Y
5Y
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
Benzinga · 09/09 14:23
Adaptimmune updates early-stage data for solid tumor candidate
U.K.-based biotech Adaptimmune Therapeutics plc (NASDAQ:ADAP</spa...
Seekingalpha · 09/09 12:44
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 09/09 12:18
BRIEF-Adaptimmune Reports Positive Data In Its Surpass Trial Outlines Plans For Advanced Clinical Development In Multiple Mage-A4 Positive Solid Tumors
BRIEF-Adaptimmune Reports Positive Data In Its Surpass Trial Outlines Plans For Advanced Clinical Development In Multiple Mage-A4 Positive Solid Tumors
Reuters · 09/09 11:20
Adaptimmune Reported 44% Objective Response Rate With a Single Dose of ADP-A2M4CD8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial.
Benzinga · 09/09 11:03
Adaptimmune Therapeutics Sees 'Robust Levels of Clinical Response' From Early-Stage Trial of Anti-Cancer Therapy
Adaptimmune Therapeutics Sees 'Robust Levels of Clinical Response' From Early-Stage Trial of Anti-Cancer Therapy
MT Newswires · 09/09 10:24
WKHS, BTU and LYG are among pre market gainers
ChannelAdvisor (ECOM) +54% <a href="https://seekingalpha.com/pr/18927145-commercehub-to-acquire-...
Seekingalpha · 09/06 12:18
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an u...
Newsfile · 08/25 12:00
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors; Tumor Infiltrating Lymphocytes (TiLs) where a patient’s own T-cells are co-administered with its next generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its clinical trials include Spearhead-1 Phase II trial with afamitres gene autoleucel; Surpass Phase I Trial with ADP-A2M4CD8, and others.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.